Axiom Investment Management LLC Acquires Shares of 4,695 AbbVie Inc. $ABBV

Axiom Investment Management LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,695 shares of the company’s stock, valued at approximately $1,021,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Vanguard Group Inc. lifted its holdings in AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. State Street Corp grew its position in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after purchasing an additional 1,119,274 shares during the period. Geode Capital Management LLC increased its stake in shares of AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. Bank of America Corp DE increased its stake in shares of AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of AbbVie during the 4th quarter worth about $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 2.4%

ABBV stock opened at $251.33 on Friday. The company has a market cap of $444.05 billion, a price-to-earnings ratio of 123.81, a PEG ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 12 month low of $187.62 and a 12 month high of $267.47. The firm has a 50-day moving average of $239.10 and a two-hundred day moving average of $224.05.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.78 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.14 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ABBV shares. Barclays raised their price target on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. BMO Capital Markets increased their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.29.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.